Nächster BIOTECH-Highflyer: MATRIX ( WKN 883845 )!

Nach dem Verdoppler Gliatech ( WKN 899190 ) nun die nächste Chance:

MATRIX ( WKN 883845 )

Werde am Wochenende mehr posten. Zunächst nur mal auf Chart, Umsätze und Kurs in USA schauen.

MfG
Star Ikone  

PUSH PUSH PUSH!
WANN MACHST DU ENDLICH HUSCH!
VERSCHWINDEST NACH AFGANISTAN
UND DREHST UNS KEINEN SCHEISS MEHR AN!  

free20682.

Der scheiss den mir SI angedreht hat hat mir heute 100 % gebracht!!!

Finde ich wirklich scheisse von dir SI was soll das :--))))

serki  

 

 

Hier mal ein interessanter Text zu Matrix, bin investiert und bleibe es! Chart anschauen...;)

Matrix Pins Hopes on EuropeWhen the FDA rejected the company's flagship injectable gel designed to stave off 'no hope' cancers, the Street savaged its shares. With a new
study under way in Europe, there's optimism that a turn-around is possible.

Vancouver, Oct 24, 2001 (smallcapcenter.com via COMTEX) -- When Matrix
Pharmaceuticals (NASDAQ: MATX) was recently hit with the FDA's rejection of its
                flagship injectable gel designed to stave off 'no hope' cancers, the Street
                savaged its shares.

                Today, Matrix is hoping promising new study results presented at the European
                Congress on Clinical Oncology (ECCO) will enable it to snag a potentially huge
                European market . . . and ultimately make to another run at FDA approval.

                Either way, it will put hope into share-shocked MATX investors.

                For Matrix, the last few months have been rocky indeed. On September 11, on a
                split vote, the FDA advisory panel expressed its uncertainty whether or not
                IntraDose(R) (cisplatin/epinephrine) showed the required efficacy in controlling
                solid tumors, specifically head and neck tumors. The vote was 9 to 3, with one
                abstention, against recommending an okay for the cancer gel.

                One observer at the meeting reportedly said that Matrix may have done it to
                itself. Although "many" panel members seemed to believe IntraDose may indeed be
                effective, "the company did a poor job of designing tests to prove it."

                And the Oncologic Drugs Advisory Committee wasn't impressed. The unanimous
                ruling was that, based on a standard approval scenario, Matrix Pharmaceutical
                had not demonstrated "substantial evidence" that IntraDose is safe and effective
                in the treatment of symptomatic recurrent head and neck cancer. In terms of
                details, the committee discussed the question of whether or not tumor response
                rates in Matrix's two earlier clinical trials were "reasonably likely to predict
                clinical benefit." The vote: six ''yes'' and seven ''no.'' Next question: Should
                Intradose be approved based on accelerated approval? Three panel members voted
                ''yes'' and nine ''no'' (with one abstention).

                Either way, MATX paid for it. On the heels of the thumbs down, sort of, from the
                drug advisory committee (read: an almost automatic rejection from the FDA
                itself), MATX was downgraded by Banc of America Securities Corporation, dropping
                from Buy to a Market Perform.

                When the trading halt came off, MATX tanked, quickly sliding from the
                late-August average of around $10 and into the uneasy netherworld of the penny
                stock, bottoming out at a 52-week low of 42 cents set on October 1, 2001.

                Since then, promising news notwithstanding, the Street still remains wary.

                At 12:34 p.m. ET, MATX was down 3.51% or 2 cents to $0.55 on average volume of
                289,500 shares versus its three-month daily average of 468,818 shares. Its
                52-week high is $17.375 posted on January 18, 2001. Note to spec investors but
                its most-recent-quarter (mrq) per-share book value is $1.31.

                At publication time, smallcapcenter.com was unable to reach the sole First Call
                covering analyst for MATX.

                Aside from shedding share value, the debacle saw the luckless Matrix lose a lot
                of bodies. On October 10, some 34 or the company's 85 workers at its Fremont,
                California headquarters and its San Diego manufacturing facility were
                pink-slipped and a decision made to sell the manufacturing facility. Although a
                Matrix spokesman put on a brave face, noting that the IntraDose rejection came
                from the advisory panel and not the FDA itself, he did allow that "Matrix
                believes it is facing an uphill battle and we want to be realistic."

                Today, Matrix is allowing itself a bit of hope, courtesy the ECCO meeting in
                Lisbon, Portugal.

                At today's meeting, Matrix presented new data which it believes has helped to
                demonstrate that IntraDose truly does control intractable and deadly solid
                tumors found in the liver, head and neck and skin. As well, data from those two
                earlier Phase III studies of IntraDose in head and neck cancer and Phase II
                studies of metastatic melanoma were tidied up and presented.

                The numbers weren't bad, not bad at all.

                First, new study results, presented for the first time and covering IntraDose
                and its effect on inoperable primary liver cancers.

                According to Matrix, the final results of the Phase II, non-randomized,
                uncontrolled, multi-center study showed that the gel achieved an overall
                response rate of 53% (27 of 51 evaluable patients) with 31% of patients showing
                a complete response --100% reduction of the tumor. (Overall response rate is
                defined as 50% plus reduction in tumor volume.) Whereas the average median
                survival rate of a liver-cancer patient is less than one year, at the time of
                data analysis, the Intradose patients showed a median survival rate almost twice
                the norm or 22.2 months. (Matrix continues to follow patients to monitor
                survival.)

                Liver cancer (hepatocellular carcinoma/HCC) is the sixth most common cancer
                worldwide, and often develops secondary to cirrhosis and chronic viral
                hepatitis. It's also a growing danger. In Europe, each year roughly 50,000 new
                cases of HCC are reported. In the United States, roughly 11,500 new cases of HCC
                are reported each year and, as Hepatitis C and its ilk continue to make inroads
                into the baby boomer population, the number is growing rapidly. Bad news for the
                stricken but surgical resection and/or liver transplantation are applicable in
                only 10% to 20% of cases. The rest die.

                ECCO delegates were also presented with Phase II study results from two
                identically designed, open-label studies which pitted Intradose against
                recurrent, metastatic melanoma. Although the melanoma was the primary target,
                doctors had the option of injecting the 'escaped' or multiple tumors in the
                patient in question.

                According to the study data, IntraDose achieved an overall primary target tumor
                response rate of 44% (11 out of 25 patients), with 20% achieving a complete
                response. Equally important but 53% of all tumors treated (130 out of 244
                tumors) in the melanoma patients achieved a response and 47% (114) achieved a
                complete response.

                The third ECCO presentation laid out results previously presented in two
                randomized, placebo-controlled Phase III studies (i.e. the studies the FDA
                advisory panel prodded and poked) involving the local control of recurrent or
                refractory head and neck cancers. Here, the overall tumor response rate was 29%
                (35 out of 119 patients) with 19% achieving a complete response.

                In terms of overall safety, Matrix says that clinical studies to date have shown
                that IntraDose is "generally well tolerated" by patients. Compared to standard
                intravenous chemotherapy which floods the bloodstream with medication, the
                'needle in the tumor' cancer-killing gel shows what the company says is an
                "favorable" adverse-event profile with a markedly lower incidence of systemic
                toxicities when compared to intravenous chemo's needle in the arm. The most
                common side effect, according to Matrix, is localized pain at the injection
                site.

                However, sometimes things did go wrong. During the Phase III study of head and
                neck cancer, six "cerebrovascular events" (CVEs) were reported; once the
                injection protocol was changed to exclude tumors directly invading or in close
                proximity to the carotid artery, no further CVEs were reported. As well, in the
                Phase II study of inoperable liver cancer, three of the 58 patients died, their
                deaths being "potentially related" to the IntraDose treatment.

                Although IntraDose is clearly not a cure-all panacea against the most deadly of
                cancers, Matrix Pharmaceuticals believes it can delay some tumors - and
                sometimes stop them cold.

                To avoid becoming cold and dead itself, Matrix clearly needs to find a market,
                fast. Which means getting regulatory approval, fast.

                In Q4 of this year, Matrix will submit an application for approval of IntraDose
                for local control of head and neck cancer to the European Medicines Evaluation
                Agency (EMEA).

                Closer to home, the company notes that the recent FDA review of the its New Drug
                Application (NDA) for IntraDose included an initial recommendation against
                marketing approval of the gel for treatment of head and neck cancer in the
                United States. Girding its loins, Matrix says that, with respect, it believes
                the FDA's position on the patient benefits of IntraDose vis-a-vis objective
                tumor response is worth re-evaluating.

                In turn, and although no dates are being mentioned, Matrix is currently planning
                its next foray to gain regulatory approval and bring IntraDose into the United
                States market.

                Or as Matrix President and Chairman Michael Casey put it: ''Matrix will continue
                to explore with the FDA the next steps for IntraDose. Head and neck cancer
                patients need new options that will locally control symptomatic tumors, which
                may cause serious complications. Matrix believes in IntraDose and its ability to
                help cancer patients and their families.''

                Based in Fremont, California, Matrix Pharmaceutical Inc. develops and
                manufactures novel drug product candidates for solid-tumor cancer. This effort
                is based on its internal research and development capabilities and through
                in-licensing of product candidates from research institutions or other
                pharmaceutical companies. Two product candidates have been, or are being,
                evaluated in human clinical trials: IntraDose (cisplatin/epinephrine) Injectable
                Gel and MPI 5020 Radiopotentiator. As well, the Company in-licenses product
                candidates for development. Example: tezacitabine (FMdC) is an intravenously
                administered therapeutic being developed for colorectal, hematologic and other
                cancers. Matrix currently owns worldwide marketing rights for all its products
                under development, except for tezacitabine in Japan.

                For the six months ended June 30, 2001, Matrix revenues rose 66% to $715
                thousand. Net loss increased 31% to $14.7 million. Revenues reflect an increased
                customer base. Net loss reflects increased S/G/A expenses due to higher
                marketing personnel costs.

                Smallcapcenter.com's advanced research department gave MATX a signal stockscore
                of 2 at 12:45 a.m. EDT on Wednesday.

                A company's stockscore is an unbiased summary of numerous technical analysis
                indicators like volume and momentum, which are combined to produce a value on a
                scale of 1-100 with 100 being the highest level.


                By David Leidl

                Copyright 2001 Stockgroup.com, All rights reserved.

 

Bin seit einigen Tagen mit einer ersten Position vertreten, möchte noch nachkaufen.

Matrix ist eine 500 - 1000% Chance auf Jahressicht.

Und jetzt wieder ruhig, sonst steigen sie zuviel.
mfg,airest  

 

Zuerst einmal Gratulation zu Gliatech, gutes Näschen so kurz vor der Abgenix Vereinbarung.

Eine Frage hätte ich aber an Dich: Woher bekommst du deine Infos über solche "ausgebombten" Nasdaq Werte?

mfg
füxlein  

sieht sehr gut aus, schaut sie Euch mal an. ;)

@Börsenfüxlein: Soll das Lob sein ( kann ich kaum glauben! ) oder erwartest Du Insiderinfos??? Solche habe ich nicht - ist alles eigene Recherche! Und die bringt nunmal am meisten ;)))

MFG
Star Ikone  

War wirklich als Lob gemeint SI. Ich kritisiere eigentlich nur, wenn ich persönlich glaube, das es angebracht ist.

Um Insiderinfos geht es eigentlich nicht, aber nur wie du auf einen Wert wie Gliatech bzw. Matrix kommst. Ich kann dir sofort 30-40 Biotechwert an der Nasdaq aufzählen, aber von Gliatech oder Matrix habe ich noch nie gehört.

Bist du in amerikanischen Boards oder gibt es spezielle Seiten im Internet für derartige Werte?

mfg
füxlein  

Im ask bei 1,06$ realtime - kein Widerstand im Chart, denke
hier ist weit mehr drin!

Schaut Sie Euch an -. nach Gliatech der nächste Verdoppler! ;)))

@füxlein: Wie gesagt, eigene Recherche und US-Kontakte.
Poste nämlich auch nur dann, wenn ich von einem Wert WIRKLICH überzeugt bin.

MfG
SI  

Unter www.island.com Kürzel: MATX eingeben und selber sehen!
Sollten die 1,18$ fallen, ist der Weg frei...alles möglich, die Rallye fängt gerade an ;)

MfG
SI  

Hast Du news aus Amiland? Geht da heute was? Neuer Hype?
Guck Dir mal die nachbörsliche Taxe an!  

Sieht sehr interessant aus, mal schauen, was da noch geht.
Halte Matrix aber long, weil ich an Kurse deutlich über 5$ glaube...

MfG
SI  

FREMONT, Calif., Sep 11, 2001 /PRNewswire via COMTEX/ -- The Oncologic Drugs Advisory Committee (ODAC) yesterday voted unanimously that, based on a standard approval scenario, Matrix Pharmaceutical, Inc. (MATX had not demonstrated substantial evidence that IntraDose(R) (cisplatin/epinephrine) Injectable Gel is safe and effective in the treatment of symptomatic recurrent head and neck cancer.
The FDA posted the draft review of the Matrix New Drug Application (NDA) on September 7, which included an initial recommendation against marketing approval of IntraDose
FREMONT, Calif., Nov 5, 2001 /PRNewswire via COMTEX/ -- As anticipated, Matrix Pharmaceutical, Inc. today announced the receipt of a non-approvable letter from the U.S. Food and Drug Administration (FDA) for IntraDose(R) (cisplatin/epinephrine) Injectable Gel. Matrix submitted a New Drug Application (NDA) for IntraDose as a treatment for recurrent or refractory head and neck cancer in January 2001. The IntraDose NDA was based on data from two, previously-conducted Phase III clinical trials.


es fällt langsam auf,dass diese Empfehlungen kommen,wenn offensichtlich die Volatilität durch immense Verkäufe gesteigert wird.Woher kriegst Du denn solche Empfehlungen?s.CAPR ähnlich  

Bekommen keine Infos, sondern recherchiere selber.
Die Nachricht vom 11.09. bzgl. Intradose ist der Grund für einen unglaublichen Kurssturz gewesen.
Dabei wurde
a) völlig vergessen, dass Matrix viel mehr in der pipeline hat
b) Intradose überarbeitet wird und zudem Europa-Zulassung beantragt ist

Mtrix wird, wenn hier ein Hype entsteht, sicher über 5$ gehen...halte long

MfG
Star Ikone  

wenn man einen kurzen detailierteren Chart reinstellt.



Es geht wohl jetzt wieder etwas abwärts, der Anstieg ein reiner Glücksfall. Als langfristiges Instrumentarium ungeeignet. Ein Anstieg wie von SI erwartet würde eine Gapschließung bedeuten, das heißt Anstieg bis auf rund sieben Dollar. Da kann man lange drauf warten.
Offensichtlich ist sich das Unternehmen auch darüber bewußt, nicht der Biotechnologie zuzugehören sondern der Pharma.

 

 

Estrich: Könnte zwar etwas dauern, aber Gap-Schliessung sehr wahrscheinlich!
Glaube auch nicht an fallenden Kurs mehr...mal sehen.

@canetti: Infos unter Kürzel matx bei www.freerealtime.com und Internetadresse.

MfG
SI  

wieder in Frankfurt (WICHTIG die deutsche WKN) ein paar Dumme gefunden, die Dir völlig überhöht Deine Teile abgekauft haben?

Kurs in US-Dollar: 0,95 = fairer Kurs in € 1,06 !
Kurs Frankfurt: 1,25 €

Oh, ich weiß: Da kündigt sich etwas an - die deutschen Insider wissen mehr als die Amis :-)

Oder anders ausgedrückt: Kursmanipulation bei 186.000 $ Umsatz ist schwerer als bei wenigen Tausend €!

Linke Bazille, ich torpediere jeden Deiner Auslands-Threads.

FMF2000
 

Es gibt einige Aktien, die solche megalomanen Gaps nach unten aufweisen. Es werden bei weitem nicht alle geschlossen. Die Chance auf weiter fallende Kurse ist zwar begrenzt, würde aber bei einer Pleite der Firma kommen. Anyway, die Chancen zum Schließen des Gaps wären da, wenn der Wert die 1,5 Dollar mit Schlußkurs knackt, besser noch die 2. Da kann man immer noch kaufen. Sag bescheid.  

Werde ich machen...;)

MfG
SI  

ich habe VOR dem Hype hier Matrix zu sammeln begonnen und zwar in den USA, in USD, ganz einfach deshalb, weil meine Auswahlmethoden bei Matrix angeschlagen haben (kannte sie vorher auch nicht).

Danach habe ich Recherche betrieben und das Investment als safe eingestuft.

Jetzt sind sie gerade zu teuer, werde nicht über $0.84 nachkaufen.

Estrich, ich verwende auch etwas Technik. Aber die Hypothese, dass alle Information im Kurs enthalten ist, auch die antizipierte, glaube ich nicht ganz.

Morgen schreibt irgend ein Arzt in irgend einem amerikanischen Provinzspital, dass er bei Tests mit einem Produkt von Matrix Erfolge gehabt hat.

Denkst du, dass du das mit Charttechnik vorweg sehen kannst?

Matrix, wie andere kleine Unternehmen haben die Phantasie in ihnen, dass ein Produkt einschlägt, sie die Lizenz verkaufen, etc... Das ist bei OTC oder OFEX Werten nun einmal so, genau wie hohe Vola.

Der letzte Kurssturz war, ohne gross analysieren zu müssen, ganz einfach brutal. Die Chance, einiges aufzuholen ist für mich weit höher, als noch einmal die Hälfte zu verlieren.

Egal, wie Matrix hier gepusht oder gebasht wird. Ich bleibe bei 500 - 1000% auf Jahresfrist, sofern die Zulassung für IntraDose in Europa oder USA in anderer Form kommt.

mfg,airest

PS.: Am NM gibt es Sanochemia 919963. Die sind mit Matrix ansatzweise vergleichbar. Der Kurs: €18.60  

kommt nicht ungelegen.

Das deutet darauf hin, dass der Anstieg vor einigen Tagen nicht (nur) auf das Ariva-Board zurück zu führen war.

Da ich bei matrix eine Riesenchance auf 12-Monatssicht sehe, ist es ohnehin besser, wenn sie nicht an einem Tag "explodieren" und am nächsten Tag wie ein leerer Sack zusammenfallen.

Aber: Werte wie Matrix gibt es viele. Wem sie nicht gefällt, kann andere kaufen. Ist sicher nicht Religion von mir, über Matrix zu reden. Bin auch nicht verliebt in sie.
mfg,airest